ArticleJournal of translational medicine2025
Pathological responses to neoadjuvant immunochemotherapy: implications for survival and recurrence in patients with locally advanced esophageal squamous cell carcinoma.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Neoadjuvant immunochemotherapy with or without radiotherapy for locally advanced esophageal squamous cell carcinoma: a pooled analysis of two prospective single-arm clinical trials.International journal of surgery (London, England) · 2026Article
- A radiomics and machine learning-based method for dynamic assessment of tumor burden after neoadjuvant therapy in esophageal cancer.BMC cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the prognostic implications of pathological responses of primary tumors (PTs) and lymph nodes (LNs) among locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients received neoadjuvant immunotherapy combined with chemotherapy (nICT).
methodsThis study enrolled patients with LA-ESCC who underwent nICT combined with esophagectomy at Jiangsu Cancer Hospital. Two senior pathologists independently and systematically evaluated the postoperative pathological specimens in a double-blind manner. Tumor regression in PTs was assessed using the Becker criteria, while LNs regression grading was optimized using Harrell's concordance index and the Akaike Information Criterion. The primary endpoints were overall survival (OS) and progression-free survival (PFS), with recurrence patterns as the secondary endpoint.
resultsA total of 141 patients with 141 PTs and 2,316 LNs were reviewed. LNs regression classified as LNs complete response (LN-CR); Partial/Poor response (LN-PR); and Truly negative LNs (LNN). The ypT0N0 rate was 21.3%. With median 41-months follow-up (IQR 22-55), the 3-year OS and PFS rates were 61.7% (95% CI 53.3-69.1%) and 48.2% (95% CI 40.2-56.4%), respectively. PTs regression grade was an independent prognostic factor for both OS and PFS (P < 0.05). Multivariable analysis demonstrated that a poorer tumor regression grade (TRG) was significantly associated with increased risks of OS and PFS (P < 0.05). Furthermore, while complete LN-CR correlated with improved PFS compared to LN-PR (P = 0.037), this association did not retain statistical significance in the multivariate analysis. Non-ypT0N0 patients exhibited higher recurrence rates than ypT0N0 (52.3% vs 33.3%, P = 0.047), primarily manifested as mixed progression.
conclusionsPTs response may constitute a more prominent determinant of both OS and PFS than LNs status, and combining these factors enhances prognostic prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.